Articles tagged "Kidney transplantation"

2018 American Transplant Congress
Competing Risk Analysis in Renal Allograft Survival: A New Perspective to an Old Problem
M. El ters,¹ B. Smith,² F. Cosio,¹ W. Kremers.²
¹Medicine, Mayo Clinic, Rochester, MN; ²Biostatistics, Mayo Clinic, Rochester, MN.
Background:Patient and graft survival after kidney transplant (KTX) is often estimated by Kaplan-Meier censoring for competing factors, e.g.death-censored graft survival. However when the competing factor…
2018 American Transplant Congress
Outcomes and Risk Factors of Kidney Transplantation from Pediatric Donors to Adult Recipients
G. Chen, X. Liu, C. Wang, Z. Wu, C. Wang, L. Chen.
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Objective To investigate the outcomes of kidney transplantation from pediatric donors to adult recipients, and explore the risk factors for DGF and graft loss after…
2018 American Transplant Congress
Having Your Cake and Eating It Too: An Aggressive Protocol for DSA Treatment Does Not Doom Patients to High Infectious Risk
A. Murthy, A. Karaballa, G. Vranic, B. Javaid, J. Moore, S. Yi, J. Verbesey, P. Abrams, S. Ghasemian, M. Cooper, A. Gilbert.
Medstar Georgetown Transplant Institute, Medstar Georgetown University Hospital, Washington, DC.
Introduction: Antibody mediated rejection (AMR) is one of the most difficult complications to treat in kidney transplantation. We previously reported on our experience with an…
2018 American Transplant Congress
The Effects of Age-Adjusted Marriage Duration on Graft Outcomes in Spousal Donor Kidney Transplantation
M. Yu,¹ J. Park,² H. Cho,¹ J. Ha,¹ C. Ahn,¹ Y. Kim,¹ H. Lee.¹
¹Seoul National University Hospital, Seoul, Korea; ²Kangwon National University Hospital, Chuncheon, Korea.
It is well known that graft survival rate in spousal donor kidney transplantation (SKT) is similar to that of living related donor kidney transplantation (LRKT)…
2018 American Transplant Congress
Belatacept-Refractory CD8⁺CD28^–CD38^hi Effector/Memory T Cells Are Targeted by mTOR Inhibition Leading to a Preferential Loss of CD40L
C. Castro Rojas,¹ A. Godarova,¹ A. Rike Shields,² R. Alloway,² M. Jordan,³ E. Woodle,² D. Hildeman.¹
¹Division of Immunobiology, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, OH; ²Division of Transplantation, University of Cincinnati College of Medicine, Cincinnati, OH; ³Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Research Foundation, Cincinnati, OH.
Calcineurin inhibitors (CNIs) and corticosteroids (CSS) have substantial untoward side effects, most notably nephrotoxicity. Consequently, the FDA approved belatacept for maintenance immunosuppression. We recently completed…
2018 American Transplant Congress
Precision (re)Phenotyping of Histologically Stable Kidney Transplants
D. Rychkov,¹ T. Sigdel,² M. Sirota,¹ M. Sarwal.²
¹Institute for Computational Health Sciences, UCSF, San Francisco, CA; ²Department of Surgery, UCSF, San Francisco, CA.
Background: Acute Rejection (AR) is the main cause of the renal failure within one year after transplantation (tx). Its earlier diagnosis is crucial for a…
2018 American Transplant Congress
Five-Year Outcomes after Randomized Treatment by Rituximab in Early Acute Antibody-Mediated Rejection in Renal Transplantation: Long Term Outcomes of the RITUX ERAH Study
E. Bailly,¹ G. Blancho,² S. Ville,² E. Morelon,³ J. Bamoulid,⁴ S. Caillard,⁵ V. Chatelet,⁶ P. Malvezzi,⁷ J. Tourret,⁸ V. Vuiblet,⁹ D. Anglicheau,¹⁰ D. Bertrand,¹¹ P. Grimbert,¹² F. Haidar,¹³ M. Hazzan,¹⁴ N. Kamar,¹⁵ P. Merville,¹⁶ C. Mousson,¹⁷ V. Pernin,¹⁸ C. Pouteil-Noble,¹⁹ R. Purgus,²⁰ J. Sayegh,²¹ P. Westeel,²² M. Büchler.¹
¹University Hospital, Tours, France; ²Institut de Transplantation-Urologie-Néphrologie, Nantes, France; ³University Hospital, Lyon Edouard Herriot, France; ⁴University Hospital, Besançon, France; ⁵University Hospital, Strasbourg, France; ⁶University Hospital, Caen, France; ⁷University Hospital, Grenoble, France; ⁸Pitié Salpêtrière Hospital, APHP, Paris, France; ⁹University Hospital, Reims, France; ¹⁰Necker Hospital, APHP, Paris, France; ¹¹University Hospital, Rouen, France; ¹²Mondor Hospital, APHP, Paris, France; ¹³Territorial Hospital, Noumea, France; ¹⁴University Hospital, Lille, France; ¹⁵University Hospital, Toulouse, France; ¹⁶University Hospital, Bordeaux, France; ¹⁷University Hospital, Dijon, France; ¹⁸University Hospital, Montpellier, France; ¹⁹University Hospital, Lyon Sud, France; ²⁰University Hospital, Marseille, France; ²¹University Hospital, Angers, France; ²²University Hospital, Amiens, France.
Background The place of rituximab in the treatment of acute antibody-mediated rejection (ABMR) is still controversial. The French multicenter double-blind, placebo-controlled RITUX ERAH study included…
2018 American Transplant Congress
The ATHENA Study: 12 Months Safety and Efficacy Data from Everolimus Combined with Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-Mycophenolate Regimen in De Novo Kidney Transplant Patients
B. Suwelack,¹ C. Sommerer,¹ D. Dragun,¹ O. Witzke,¹ C. Hugo,¹ N. Kamar,² P. Merville,² A. Hauser,¹ P. Schenker,¹ M. Junge,³ B. Nashan,¹ F. Thaiss.¹
¹Athena Study Group, Germany; ²Athena Study Group, France; ³Novartis, Pharma, Germany.
The ATHENA study was set up to compare efficacy and safety of everolimus [EVR] combined with tacrolimus [TAC] or cyclosporine A [CyA] vs. a mycophenolic…
2018 American Transplant Congress
Th17 and NK Responses Are Differentially Induced in Renal Allografts According to Recipient Murine Cytomegalovirus Dose and Strain
M. Shimamura,¹ M. Li,² S. Boddeda,¹ B. Chen,² Q. Zeng,¹ T. Schoeb,² V. Velazquez.¹
¹Center for Vaccines and Immunity and Dept. of Pediatric Infectious Diseases, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH; ²Depts. of Pediatric Infectious Diseases, Pathology, and Genetics, University of Alabama at Birmingham, Birmingham, AL.
Purpose: To study the impact of cytomegalovirus (CMV) recipient positive (R+) serostatus upon renal allograft injury, murine CMV (MCMV) D+/R+ kidney transplants using recipients infected…
2018 American Transplant Congress
Tissue Talks: Graft´s Histological Findings 10 Years after Belatacept or CNI
G. Mondragon-Ramirez,¹ N. Uribe-Uribe,² J. Arreola-Guerra,⁵ R. Reyes-Acevedo,⁵ M. Vilatoba,³ J. Furuzawa-Carballeda,⁴ A. Lopez-Toledo,¹ G. Mondragon-Salgado,¹ J. Alberu.³
¹Inst Mex de Trasplantes, Cuernavaca, Mexico; ²Pathology, Inst Nal de C. Médicas y Nutrición SZ, Mexico City, Mexico; ³Transplantation, Inst Nal de C. Médicas y Nutrición SZ, Mexico City, Mexico; ⁴Immunology, Inst Nal de C. Médicas y Nutrición SZ, Mexico City, Mexico; ⁵Transplantation, C Hospital Miguel Hidalgo, Aguascalientes, Mexico.
The BENEFIT study demonstrated that 7 yrs after kidney transplantation (KT), mean eGFR, patient and graft survival, were significantly higher in the belatacept group than…